Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION)

  • STATUS
    Recruiting
  • End date
    Dec 31, 2028
  • participants needed
    124
  • sponsor
    Seoul National University Hospital
Updated on 19 February 2024
cancer
hysterectomy
squamous cell carcinoma
adenocarcinoma
carcinoma
uterine cervix
serum bilirubin
open surgery
adenosquamous carcinoma
cervical disease
cervical carcinoma
cervical cancer stage
minimally invasive surgery
cervical cancer
stage ib1 cervical cancer

Summary

The SOLUTION trial aims to show the efficacy and safety of performing radical hysterectomy by minimally invasive surgery using an endoscopic stapler in patients with cervical cancer stage IB1 (FIGO staging 2009) and thus to prove that minimally invasive surgery is non-inferior to open surgery.

Description

Cervical cancer is the 4th most common gynecologic cancer and treatment in early stages consists of surgery, chemotherapy, or radiation therapy. Surgical methods are simple or radical hysterectomy and pelvic and para-aortic lymph node dissection either done in an open manner or minimally invasive surgery (robotic or laparoscopic). However, a phase III cinical trial in 2018 comparing the safety and efficacy between minimally invasive surgery and open surgery in performing radical hysterectomy, 'Laparoscopic Approach to Cervical Cancer' (LACC), showed that open surgery is safer than minimally invasive surgery. Possible causes of such results are as follows:

  1. Carbon dioxide is supplied during laparoscopic operations to maintain capnoperitoneum, which can cause the implantation and proliferation of tumor cells exposed to the peritoneal cavity.
  2. Insertions of uterine manipulators into the endometrial cavity is commonly done, which can cause tumor cells to travel to both salpinges.
  3. Tumor cells can be exposed to the peritoneal cavity when the cervix is exposed during intracorporeal colpotomy.
  4. Tumor cells exposed to the peritoneal cavity can travel upwards when the patient's position is maintained in the Trendelenburg position during minimally invasive operations, leading to distant metastasis.

Based on the above-mentioned hypothesis, the following methods could be applied to minimize the exposure of tumor cells to the peritoneal cavity.

  1. The application of a vaginal tube instead of a uterine manipulator to prevent tumor cells from traveling to the salpinges.
  2. The ligation of both salpinges prior to insertion of a vaginal tube to block the travel of tumor cells.
  3. The performance of extracorporeal colpotomy instead to prevent the exposure of tumor cells inside the peritoneal cavity.

Although it would be favorable to perform all the forementioned methods, extracorporeal colpotomy is difficult to perform especially in menopausal patients with atrophic vaginitis or patients with no sexual experience. Thus, an alternative method is to use an endoscopic stapler which can simultaneously cut and suture the cervix into a vaginal stump, which can prevent tumor cells from being exposed to the peritoneal cavity.

In conclusion, this clinical trial aims to show the efficacy and safety of performing radical hysterectomy by minimally invasive surgery using an endoscopic stapler in patients with cervical cancer stage IB1 (FIGO staging 2009) and thus to prove that minimally invasive surgery is non-inferior to open surgery.

Details
Condition Cervical Cancer, Cervical Cancer, Uterine Cancer, Uterine Cancer, Minimally Invasive Surgery, Cervical Cancer Stage IB1
Age 20-100 years
Treatment Minimally invasive surgery using endoscopic stapler
Clinical Study IdentifierNCT04370496
SponsorSeoul National University Hospital
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Females, aged 20 years or older
Histologically confirmed primary squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix
Patients with FIGO stage IB1 (FIGO staging 2009)
stromal invasion>5 mm or 7 mm <lesion size 4 cm
Patients undergoing either type B or C hysterectomy (Querleu-Morrow classification)
Patients with normal bone marrow, renal and hepatic function
WBC > 3.0x10^9 cells/L
Platelets > 100x10^9 cells/L
Serum creatinine 1.5 mg/dL
Serum total bilirubin <1.5 x normal range and AST/SGOT or ALT/SGPT <3 x normal range
ECOG performance status 0 or 1
Synchronous cancer with no evidence of recurrence during the past 5 years
Informed consent of patient

Exclusion Criteria

Any histological type other than squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix
Tumor size greater than 4 cm
Patients with FIGO less than stage IA2 or greater than IB2 (FIGO staging 2009)
stromal invasion 5 mm and lesion size 7 mm (less than IA2)
or lesion size> 4 cm (greater than IB2)
Patients with evidence of metastatic disease by conventional imaging studies, enlarged pelvic or aortic lymph nodes greater than 2 cm, or histologically positive lymph nodes
Patients in pregnancy
Patients with a history of pelvic or abdominal radiotherapy
Patients with contraindication of surgery (serious concomitant systemic disorders incompatible with the study to be decided at the discretion of the investigator)
Patients who agree to intra-operative lymphatic mapping (IOLM) must not have
Known allergies to triphenylmethane compounds
History of retroperitoneal surgery
History of pelvic irradiation
Cold knife or LEEP cone biopsy within 4 weeks of enrollment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.